Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feedergsk.com
Press releases
Get the latest updates from Press releases directly as they happen.
Follow now 479 followers
Latest posts
Last updated 5 days ago
GSK enters agreement to acquire IDRx, Inc.
5 days ago
Acquisition adds to GSK’s growing portfolio in gastrointestinal (GI) cancers
GSK’s Shingrix new prefilled syringe presentation accepted for review by US FDA
8 days ago
If approved, the new presentation will offer a convenient administration option to...
GSK’s B7-H3-targeted antibody-drug conjugate, GSK’227, receives US FDA Breakthrough Therapy Designation in late-line relapsed or refractory osteosarcoma
11 days ago
Regulatory designation based on promising early data in this rare bone cancer.
GSK’s Nucala (mepolizumab) approved in China for treatment of adults with chronic rhinosinusitis with nasal polyps
15 days ago
This is the third indication for mepolizumab in China for an IL-5...
GSK announces FIRST trial met its primary endpoint of progression free survival in first line advanced ovarian cancer
29 days ago
GSK announces headline results from the FIRST-ENGOT-OV44 phase III trial.
ViiV Healthcare announces CHMP positive opinion for Vocabria + Rekambys, the first and only complete long-acting HIV treatment, for adolescents in Europe
about 1 month ago
Vocabria + Rekambys is the first and only complete long-acting regimen for...
GSK’s B7-H3-targeted antibody-drug conjugate, GSK’227, receives EMA Priority Medicines (PRIME) Designation in relapsed extensive-stage small-cell lung cancer
about 1 month ago
Regulatory designation based on promising preliminary clinical data.
Jemperli (dostarlimab) receives US FDA Breakthrough Therapy Designation for locally advanced dMMR/MSI-H rectal cancer
about 1 month ago
Designation based on data showing no evidence of disease in 100% of...
Jemperli (dostarlimab) plus chemotherapy receives positive CHMP opinion to expand approval to all adult patients with primary advanced or recurrent endometrial cancer
about 1 month ago
Positive opinion based on statistically significant and clinically meaningful progression-free and overall...
Blenrep shows significant overall survival benefit, reducing the risk of death by 42% in multiple myeloma at or after first relapse
about 1 month ago
DREAMM-7 trial shows sustained overall survival benefit for Blenrep (belantamab mafodotin) combination...
US FDA accepts GSK’s submission for the use of Nucala (mepolizumab) in COPD
about 1 month ago
Nucala could be the first approved biologic with monthly dosing for patients...
Blenrep (belantamab mafodotin) combination accepted for priority review in China in relapsed/refractory multiple myeloma
about 1 month ago
Regulatory submission supported by phase III head-to-head DREAMM-7 trial showing statistically significant...